{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:45:13Z","timestamp":1785843913795,"version":"3.56.0"},"reference-count":119,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cytometry Part B Clinical"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Measurable residual disease (MRD) assessment is a key determinant of risk stratification and treatment modification in B\u2010cell acute lymphoblastic leukemia (B\u2010ALL). Multicolour flow cytometry (MFC) is a globally adopted rapid and sensitive MRD technique. However, technical practices remain significantly variable across laboratories, compromising assay sensitivity, reproducibility, and comparability. Currently, systemic recommendations providing guidelines on the technical aspects of MFC\u2010MRD in B\u2010ALL are unavailable. The Cytometry Society (TCS)\u2010India undertook a structured consensus process to standardize technical aspects of MFC\u2010MRD testing. A two\u2010round Delphi survey was conducted among laboratory professionals and clinicians across India to capture the prevailing practices and priorities. Consensus recommendations were prepared through survey findings and further refined during an in\u2010person consensus congress with national and international experts from Australia, Egypt, Spain, and Russia. This document provides comprehensive recommendations across pre\u2010analytic, analytic, and post\u2010analytic phases of MFC\u2010MRD including minimal antibody panel, best practices for sample collection, transport, and processing, Instrument setup, quality control, acquisition targets, gating strategies, approaches for LOD\/LLOQ definition, hemodilution assessment, etc. A structured MRD report format with quality caveats is also provided. The recommendations are categorized into \u201cMust,\u201d \u201cPreferred,\u201d and \u201cAcceptable\u201d levels to suit diverse resource settings while promoting harmonization. Implementation of these standards will enhance assay sensitivity, reproducibility, and comparability, thereby strengthening MRD\u2010guided clinical decision\u2010making in B\u2010ALL.<\/jats:p>","DOI":"10.1002\/cyto.b.70055","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:02:56Z","timestamp":1785841376000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Consensus recommendations for technical standardization of flow cytometric measurable residual disease assessment in\n                    <scp>B<\/scp>\n                    \u2010cell acute lymphoblastic leukemia: A report from\n                    <scp>The Cytometry Society, India<\/scp>"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9030-0415","authenticated-orcid":false,"given":"Prashant","family":"Tembhare","sequence":"first","affiliation":[{"name":"Department of Hematopathology and Cytogenetics, ACTREC, Tata Memorial Center Homi Bhabha National Institute (HBNI) University  Navi Mumbai India"},{"name":"Clinical Division The Cytometry Society\u2010India  Hyderabad Telangana India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4099-4578","authenticated-orcid":false,"given":"Kunal","family":"Sehgal","sequence":"additional","affiliation":[{"name":"Clinical Division The Cytometry Society\u2010India  Hyderabad Telangana India"},{"name":"Neuberg Sehgal Path Lab Private Limited  Mumbai India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0851-886X","authenticated-orcid":false,"given":"Karthik","family":"Bommannan","sequence":"additional","affiliation":[{"name":"Clinical Division The Cytometry Society\u2010India  Hyderabad Telangana India"},{"name":"Department of Oncopathology Cancer Institute (W.I.A.)  Chennai India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8285-2092","authenticated-orcid":false,"given":"Khaliqur","family":"Rahman","sequence":"additional","affiliation":[{"name":"Clinical Division The Cytometry Society\u2010India  Hyderabad Telangana India"},{"name":"Department of Hematology (Laboratory) SGPGIMS  Lucknow Uttar Pradesh India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Jain","sequence":"additional","affiliation":[{"name":"Clinical Division The Cytometry Society\u2010India  Hyderabad Telangana India"},{"name":"Flow Cytometry Laboratory Geneflow Labs  Gurugram India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Dayal","sequence":"additional","affiliation":[{"name":"Clinical Division The Cytometry Society\u2010India  Hyderabad Telangana India"},{"name":"Haematopathology Section Max Super Specialty Hospital  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sitaram","family":"Ghogale","sequence":"additional","affiliation":[{"name":"Department of Hematopathology and Cytogenetics, ACTREC, Tata Memorial Center Homi Bhabha National Institute (HBNI) University  Navi Mumbai India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananthvikas","family":"Jayaram","sequence":"additional","affiliation":[{"name":"Clinical Division The Cytometry Society\u2010India  Hyderabad Telangana India"},{"name":"Neuberg Anand Reference Laboratory  Bengaluru India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4406-8299","authenticated-orcid":false,"given":"Man Updesh Singh","family":"Sachdeva","sequence":"additional","affiliation":[{"name":"Clinical Division The Cytometry Society\u2010India  Hyderabad Telangana India"},{"name":"Department of Hematology Postgraduate Institute of Medical Sciences and Research (PGIMER)  Chandigarh India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5364-4086","authenticated-orcid":false,"given":"Ritu","family":"Gupta","sequence":"additional","affiliation":[{"name":"Laboratory Oncology Unit IRCH  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Papagudi G.","family":"Subramanian","sequence":"additional","affiliation":[{"name":"Department of Hematopathology and Cytogenetics, ACTREC, Tata Memorial Center Homi Bhabha National Institute (HBNI) University  Navi Mumbai India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhu","family":"Manivannan","sequence":"additional","affiliation":[{"name":"Department of Pathology Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER)  Pondicherry India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohan","family":"Galande","sequence":"additional","affiliation":[{"name":"Hematopathology Laboratory Unipath Specialty Laboratory Ltd.  Ahmedabad Gujrat India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manasi","family":"Mundada","sequence":"additional","affiliation":[{"name":"Basavatarakam Indo\u2010American Cancer Hospital and Research Institute  Hyderabad India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asish","family":"Rath","sequence":"additional","affiliation":[{"name":"Clinical Division The Cytometry Society\u2010India  Hyderabad Telangana India"},{"name":"Laboratory Hematology Tata Medical Center  Kolkata India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phaneendra","family":"Datari","sequence":"additional","affiliation":[{"name":"Department of Haematology Christian Medical College  Vellore India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sweta","family":"Rajpal","sequence":"additional","affiliation":[{"name":"Department of Hematopathology and Cytogenetics, ACTREC, Tata Memorial Center Homi Bhabha National Institute (HBNI) University  Navi Mumbai India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6505-7898","authenticated-orcid":false,"given":"Gaurav","family":"Chatterjee","sequence":"additional","affiliation":[{"name":"Department of Hematopathology and Cytogenetics, ACTREC, Tata Memorial Center Homi Bhabha National Institute (HBNI) University  Navi Mumbai India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilesh","family":"Deshpande","sequence":"additional","affiliation":[{"name":"Department of Hematopathology and Cytogenetics, ACTREC, Tata Memorial Center Homi Bhabha National Institute (HBNI) University  Navi Mumbai India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotteeswari","family":"Kathirvel","sequence":"additional","affiliation":[{"name":"Department of Haematology Christian Medical College  Vellore India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuldeep","family":"Singh","sequence":"additional","affiliation":[{"name":"Flow Cytometry Laboratory Geneflow Labs  Gurugram India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhausaheb","family":"Bagal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Center HBNI University  Mumbai India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Punatar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and BMT ACTREC, Tata Memorial Center, HBNI University  Navi Mumbai Maharashtra India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambreen","family":"Pandrowala","sequence":"additional","affiliation":[{"name":"B. J. Wadia Hospital for Children  Mumbai India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetan","family":"Dhamne","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Tata Memorial Center HBNI University  Mumbai India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Handoo","sequence":"additional","affiliation":[{"name":"Clinical Division The Cytometry Society\u2010India  Hyderabad Telangana India"},{"name":"BLK Super Speciality Hospital  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Julio\u2010Javier","sequence":"additional","affiliation":[{"name":"Cytometry Service University of Salamanca  Salamanca Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0889-6986","authenticated-orcid":false,"given":"Alexander","family":"Popov","sequence":"additional","affiliation":[{"name":"National Research Center for Pediatric Hematology Oncology and Immunology  Moscow Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia","family":"Salem","sequence":"additional","affiliation":[{"name":"Clinical Pathology Department, Faculty of Medicine Mansoura University  Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Westerman","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Orfao","sequence":"additional","affiliation":[{"name":"Department of Medicine Cancer Research and the Cytometry Service of the University of Salamanca  Salamanca Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"issue":"9","key":"e_1_2_6_2_1","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/cyto.a.24013","article-title":"Application settings versus fixed photomultiplier tube voltages for optimal cytometer stability over time, and effect on reusing a compensation matrix","volume":"97","author":"Andersen M. N.","year":"2020","journal-title":"Cytometry Part A: The Journal of the International Society for Analytical Cytology"},{"issue":"1","key":"e_1_2_6_3_1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/cyto.b.21228","article-title":"Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting","volume":"90","author":"Arroz M.","year":"2016","journal-title":"Cytometry Part B, Clinical Cytometry"},{"issue":"11","key":"e_1_2_6_4_1","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/cyto.a.23016","article-title":"International Society for Advancement of cytometry (ISAC) flow cytometry shared resource laboratory (SRL) best practices","volume":"89","author":"Barsky L. W.","year":"2016","journal-title":"Cytometry Part A: The Journal of the International Society for Analytical Cytology"},{"issue":"3","key":"e_1_2_6_5_1","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1053\/j.seminhematol.2020.06.003","article-title":"Monitoring MRD in ALL: Methodologies, technical aspects and optimal time points for measurement","volume":"57","author":"Bartram J.","year":"2020","journal-title":"Seminars in Hematology"},{"issue":"1","key":"e_1_2_6_6_1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/cyto.b.20153","article-title":"Thematic workshop on fluorescence compensation settings in multicolor flow cytometry","volume":"72","author":"Bayer J.","year":"2007","journal-title":"Cytometry Part B, Clinical Cytometry"},{"issue":"12","key":"e_1_2_6_7_1","doi-asserted-by":"crossref","first-page":"819","DOI":"10.4049\/immunohorizons.2300066","article-title":"Side\u2010by\u2010side comparison of compensation beads used in polychromatic flow cytometry","volume":"7","author":"Bhowmick D.","year":"2023","journal-title":"ImmunoHorizons"},{"issue":"13","key":"e_1_2_6_8_1","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1080\/10428194.2019.1625043","article-title":"CD19 negative and dim precursor B\u2010lineage acute lymphoblastic leukemias: Real\u2010world challenges in a targeted\u2010immunotherapy era","volume":"60","author":"Bommannan B. K. K.","year":"2019","journal-title":"Leukemia & Lymphoma"},{"issue":"3","key":"e_1_2_6_9_1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2144\/000113382","article-title":"Antibody validation","volume":"48","author":"Bordeaux J.","year":"2010","journal-title":"BioTechniques"},{"issue":"8","key":"e_1_2_6_10_1","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1182\/blood-2015-03-633685","article-title":"Prognostic significance of minimal residual disease in high risk B\u2010ALL: A report from Children's oncology group study AALL0232","volume":"126","author":"Borowitz M. J.","year":"2015","journal-title":"Blood"},{"issue":"8","key":"e_1_2_6_11_1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14082011","article-title":"Quality assessment of a large multi\u2010center flow cytometric dataset of acute myeloid leukemia patients\u2014a EuroFlow study","volume":"14","author":"Bras A. E.","year":"2022","journal-title":"Cancers"},{"issue":"14","key":"e_1_2_6_12_1","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1182\/blood-2016-12-725804","article-title":"Minimal residual disease\u2010guided therapy in childhood acute lymphoblastic leukemia","volume":"129","author":"Campana D.","year":"2017","journal-title":"Blood"},{"issue":"3","key":"e_1_2_6_13_1","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.cll.2007.05.010","article-title":"More than just quality control","volume":"27","author":"Carey J. L.","year":"2007","journal-title":"Clinics in Laboratory Medicine"},{"issue":"6","key":"e_1_2_6_14_1","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/cyto.b.21371","article-title":"Stabilization of pre\u2010optimized multicolor antibody cocktails for flow cytometry applications","volume":"92","author":"Chan R. C.","year":"2017","journal-title":"Cytometry Part B, Clinical Cytometry"},{"issue":"1","key":"e_1_2_6_15_1","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/ejh.14102","article-title":"15\u2010color highly sensitive flow cytometry assay for post anti\u2010CD19 targeted therapy (anti\u2010CD19\u2010CAR\u2010T and blinatumomab) measurable residual disease assessment in B\u2010lymphoblastic leukemia\/lymphoma: Real\u2010world applicability and challenges","volume":"112","author":"Chatterjee G.","year":"2024","journal-title":"European Journal of Haematology"},{"issue":"2","key":"e_1_2_6_16_1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.blre.2016.09.006","article-title":"Monitoring minimal residual disease in acute leukemia: Technical challenges and interpretive complexities","volume":"31","author":"Chen X.","year":"2017","journal-title":"Blood Reviews"},{"issue":"1","key":"e_1_2_6_17_1","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/cyto.b.21482","article-title":"A novel flow cytometric assay for detection of residual disease in patients with B\u2010lymphoblastic leukemia\/lymphoma post anti\u2010CD19 therapy","volume":"94","author":"Cherian S.","year":"2018","journal-title":"Cytometry Part B, Clinical Cytometry"},{"issue":"1","key":"e_1_2_6_18_1","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29990","article-title":"High frequency of heat shock protein 27 overexpression is a highly effective, high\u2010coverage marker for minimal residual disease detection in children with B\u2010cell acute lymphoblastic leukemia","volume":"70","author":"Chou S. W.","year":"2023","journal-title":"Pediatric Blood & Cancer"},{"issue":"4","key":"e_1_2_6_19_1","doi-asserted-by":"crossref","first-page":"e365","DOI":"10.1016\/j.clml.2020.11.010","article-title":"Measurable residual disease assessment and allogeneic transplantation as consolidation therapy in adult acute lymphoblastic leukemia in Colombia","volume":"21","author":"Combariza J. F.","year":"2021","journal-title":"Clinical Lymphoma, Myeloma & Leukemia"},{"issue":"12","key":"e_1_2_6_20_1","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1002\/eji.202170126","article-title":"Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)","volume":"51","author":"Cossarizza A.","year":"2021","journal-title":"European Journal of Immunology"},{"issue":"23","key":"e_1_2_6_21_1","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1182\/blood-2010-12-324004","article-title":"New markers for minimal residual disease detection in acute lymphoblastic leukemia","volume":"117","author":"Coustan\u2010Smith E.","year":"2011","journal-title":"Blood"},{"issue":"12","key":"e_1_2_6_22_1","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1007\/s11095-009-9972-5","article-title":"An approach to the validation of flow cytometry methods","volume":"26","author":"Cunliffe J.","year":"2009","journal-title":"Pharmaceutical Research"},{"issue":"5","key":"e_1_2_6_23_1","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/cyto.b.21105","article-title":"Validation of cell\u2010based fluorescence assays: Practice guidelines from the ICSH and ICCS \u2010 part II \u2010 preanalytical issues","volume":"84","author":"Davis B. H.","year":"2013","journal-title":"Cytometry Part B, Clinical Cytometry"},{"issue":"3","key":"e_1_2_6_24_1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/cyto.b.20584","article-title":"Improved compensation of the fluorochrome AmCyan using cellular controls","volume":"80","author":"DiGiuseppe J. A.","year":"2011","journal-title":"Cytometry Part B, Clinical Cytometry"},{"key":"e_1_2_6_25_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2019.06.007","article-title":"Impact of blood storage and sample handling on quality of high dimensional flow cytometric data in multicenter clinical research","volume":"475","author":"Diks A. M.","year":"2019","journal-title":"Journal of Immunological Methods"},{"issue":"1","key":"e_1_2_6_26_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ijlh.12344","article-title":"The evolution of guidelines for the validation of flow cytometric methods","volume":"37","author":"Du L.","year":"2015","journal-title":"International Journal of Laboratory Hematology"},{"issue":"1","key":"e_1_2_6_27_1","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/cyto.b.21518","article-title":"AIEOP\u2010BFM consensus guidelines 2016 for flow cytometric immunophenotyping of pediatric acute lymphoblastic leukemia","volume":"94","author":"Dworzak M. N.","year":"2018","journal-title":"Cytometry Part B, Clinical Cytometry"},{"issue":"6","key":"e_1_2_6_28_1","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1182\/blood.V99.6.1952","article-title":"Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia","volume":"99","author":"Dworzak M. N.","year":"2002","journal-title":"Blood"},{"issue":"6","key":"e_1_2_6_29_1","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/cyto.b.20430","article-title":"Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasible","volume":"74","author":"Dworzak M. N.","year":"2008","journal-title":"Cytometry Part B, Clinical Cytometry"},{"key":"e_1_2_6_30_1","unstructured":"EuroFlow Consortium. (2018).EuroFlow SOP for bulk lysis in MRD panels version 1.3 EuroFlow.https:\/\/euroflow.org\/protocols\/"},{"issue":"12","key":"e_1_2_6_31_1","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/cyto.a.23021","article-title":"Sample preparation for flow cytometry benefits from some lateral thinking","volume":"89","author":"Filby A.","year":"2016","journal-title":"Cytometry Part A: The Journal of the International Society for Analytical Cytology"},{"issue":"10","key":"e_1_2_6_32_1","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores\u2010Montero J.","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"e_1_2_6_33_1","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/j.clml.2022.10.008","article-title":"Standardizing clinical workflow for assessing minimal residual disease by flow cytometry in multiple myeloma","volume":"23","author":"Foureau D. M.","year":"2023","journal-title":"Clinical Lymphoma, Myeloma & Leukemia"},{"issue":"9","key":"e_1_2_6_34_1","doi-asserted-by":"crossref","first-page":"e685","DOI":"10.1016\/j.clml.2025.05.016","article-title":"Delphi survey on measurable residual disease in multiple myeloma: Prevailing practices and the way forward in India","volume":"25","author":"Gajendra S.","year":"2025","journal-title":"Clinical Lymphoma, Myeloma & Leukemia"},{"issue":"4","key":"e_1_2_6_35_1","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/cyto.b.21373","article-title":"CD19 negative precursor B acute lymphoblastic leukemia (B\u2010ALL)\u2010immunophenotypic challenges in diagnosis and monitoring: A study of three cases","volume":"92","author":"Ghodke K.","year":"2017","journal-title":"Cytometry Part B, Clinical Cytometry"},{"issue":"2","key":"e_1_2_6_36_1","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1182\/blood.2023020621","article-title":"CD19\/CD22 targeting with cotransduced CAR T cells to prevent antigen\u2010negative relapse after CAR T\u2010cell therapy for B\u2010cell ALL","volume":"143","author":"Ghorashian S.","year":"2024","journal-title":"Blood"},{"issue":"1","key":"e_1_2_6_37_1","first-page":"283","article-title":"Effects of different media on human T regulatory cells phenotype","volume":"35","author":"G\u0141aczynska M.","year":"2021","journal-title":"In Vivo (Athens, Greece)"},{"key":"e_1_2_6_38_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2017.07.013","article-title":"Standardization of 8\u2010color flow cytometry across different flow cytometer instruments: A feasibility study in clinical laboratories in Switzerland","volume":"475","author":"Glier H.","year":"2019","journal-title":"Journal of Immunological Methods"},{"key":"e_1_2_6_39_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2019.112680","article-title":"Comments on EuroFlow standard operating procedures for instrument setup and compensation for BD FACS canto II, Navios and BD FACS lyric instruments","volume":"475","author":"Glier H.","year":"2019","journal-title":"Journal of Immunological Methods"},{"key":"e_1_2_6_40_1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/978-1-4939-9650-6_14","article-title":"Quality control of immunophenotyping","volume":"2032","author":"Greig B.","year":"2019","journal-title":"Methods in Molecular Biology (Clifton, N.J.)"},{"issue":"4","key":"e_1_2_6_41_1","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/cyto.b.21866","article-title":"CD304\/neuropilin\u20101 is a very useful and dependable marker for the measurable residual disease assessment of B\u2010cell precursor acute lymphoblastic leukemia","volume":"98","author":"Gudapati P.","year":"2020","journal-title":"Cytometry Part B, Clinical Cytometry"},{"issue":"12","key":"e_1_2_6_42_1","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202249917","article-title":"Guidelines for DC preparation and flow cytometric analysis of human lymphohematopoietic tissues","volume":"53","author":"Heger L.","year":"2023","journal-title":"European Journal of Immunology"},{"issue":"26","key":"e_1_2_6_43_1","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 update on MRD in acute myeloid leukemia: A consensus document from the European LeukemiaNet MRD working party","volume":"138","author":"Heuser M.","year":"2021","journal-title":"Blood"},{"issue":"3","key":"e_1_2_6_44_1","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1182\/blood.2023022783","article-title":"CD19 occupancy may drive CARs further","volume":"143","author":"Hirayama A. V.","year":"2024","journal-title":"Blood"},{"key":"e_1_2_6_45_1","unstructured":"https:\/\/euroflow.org\/protocols\/ n.d."},{"issue":"10","key":"e_1_2_6_46_1","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1097\/ACM.0000000000001812","article-title":"The use of the Delphi and other consensus group methods in medical education research: A review","volume":"92","author":"Humphrey\u2010Murto S.","year":"2017","journal-title":"Academic Medicine: Journal of the Association of American Medical Colleges"},{"issue":"5","key":"e_1_2_6_47_1","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.3109\/10428194.2014.963579","article-title":"CD19\u2010negative B\u2010lymphoblastic leukemia associated with hypercalcemia, lytic bone lesions and aleukemic presentation","volume":"56","author":"Hussein S.","year":"2015","journal-title":"Leukemia & Lymphoma"},{"issue":"19","key":"e_1_2_6_48_1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14194937","article-title":"Flow cytometric analysis of bone marrow particle cells for measuring minimal residual disease in multiple myeloma","volume":"14","author":"Jiang D.","year":"2022","journal-title":"Cancers"},{"issue":"4","key":"e_1_2_6_49_1","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/bjh.12789","article-title":"Guidelines on the use of multicolour flow cytometry in the diagnosis of haematological neoplasms. British Committee for Standards in Haematology","volume":"165","author":"Johansson U.","year":"2014","journal-title":"British Journal of Haematology"},{"issue":"3","key":"e_1_2_6_50_1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/cytob.21154","article-title":"Tandem dyes: Stability in cocktails and compensation considerations","volume":"86","author":"Johansson U.","year":"2014","journal-title":"Cytometry Part B, Clinical Cytometry"},{"issue":"2","key":"e_1_2_6_51_1","doi-asserted-by":"crossref","first-page":"90","DOI":"10.4103\/0973-6247.42698","article-title":"Quality issues of laboratory reagents","volume":"2","author":"Kahar M. A.","year":"2008","journal-title":"Asian Journal of Transfusion Science"},{"issue":"2","key":"e_1_2_6_52_1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/cyto.a.22581","article-title":"Quality assessment program for EuroFlow protocols: Summary results of four\u2010year (2010\u20102013) quality assurance rounds","volume":"87","author":"Kalina T.","year":"2015","journal-title":"Cytometry Part A: The Journal of the International Society for Analytical Cytology"},{"issue":"9","key":"e_1_2_6_53_1","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/leu.2012.122","article-title":"EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols","volume":"26","author":"Kalina T.","year":"2012","journal-title":"Leukemia"},{"issue":"10","key":"e_1_2_6_54_1","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/cyto.a.22935","article-title":"Standardization and quality control for high\u2010dimensional mass cytometry studies of human samples","volume":"89","author":"Kleinsteuber K.","year":"2016","journal-title":"Cytometry Part A: The Journal of the International Society for Analytical Cytology"},{"key":"e_1_2_6_55_1","article-title":"A semi\u2010automated approach to preparing antibody cocktails for immunophenotypic analysis of human peripheral blood","volume":"108","author":"Koguchi Y.","year":"2016","journal-title":"Journal of Visualized Experiments"},{"issue":"6","key":"e_1_2_6_56_1","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1053\/j.semdp.2023.10.001","article-title":"Updates on lymphoblastic leukemia\/lymphoma classification and minimal\/measurable residual disease analysis","volume":"40","author":"Kovach A. E.","year":"2023","journal-title":"Seminars in Diagnostic Pathology"},{"issue":"6","key":"e_1_2_6_57_1","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/cyto.a.20396","article-title":"Data quality assessment of ungated flow cytometry data in high throughput experiments","volume":"71","author":"Le Meur N.","year":"2007","journal-title":"Cytometry Part A: The Journal of the International Society for Analytical Cytology"},{"issue":"5","key":"e_1_2_6_58_1","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/cyto.b.22135","article-title":"CD19\u2010negative B\u2010cell precursors in bone marrow: A potential mimicker for CD19\u2010negative B\u2010lymphoblastic leukemia by flow cytometry in patients with anti\u2010CD19 treatment","volume":"104","author":"Li W.","year":"2023","journal-title":"Cytometry Part B, Clinical Cytometry"},{"issue":"6","key":"e_1_2_6_59_1","doi-asserted-by":"crossref","first-page":"e346","DOI":"10.1097\/MPH.0000000000001412","article-title":"Minimal residual disease\u2010guided risk Restratification and therapy improves the survival of childhood acute lymphoblastic leukemia: Experience from a tertiary Children's Hospital in China","volume":"41","author":"Liao C.","year":"2019","journal-title":"Journal of Pediatric Hematology\/Oncology"},{"key":"e_1_2_6_60_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2025.120567","article-title":"Technologic advances in flow cytometry","volume":"578","author":"Liu X.","year":"2026","journal-title":"Clinica Chimica Acta; International Journal of Clinical Chemistry"},{"issue":"1","key":"e_1_2_6_61_1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/cyto.b.20429","article-title":"Normalization of bone marrow aspirates for hemodilution in flow cytometric analyses","volume":"76","author":"Loken M. R.","year":"2009","journal-title":"Cytometry Part B, Clinical Cytometry"},{"issue":"5","key":"e_1_2_6_62_1","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/bjh.15086","article-title":"Pre\u2010 and post\u2010transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia","volume":"180","author":"Lovisa F.","year":"2018","journal-title":"British Journal of Haematology"},{"issue":"2","key":"e_1_2_6_63_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2025.103775","article-title":"Protocol for in\u2010plate staining of clinical peripheral blood mononuclear cell samples for high\u2010throughput analysis via spectral flow cytometry","volume":"6","author":"Marciello I.","year":"2025","journal-title":"STAR Protocols"},{"issue":"23","key":"e_1_2_6_64_1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13236148","article-title":"An extensive quality control and quality assurance (QC\/QA) program significantly improves inter\u2010laboratory concordance rates of flow\u2010cytometric minimal residual disease assessment in acute lymphoblastic leukemia: An I\u2010BFM\u2010FLOW\u2010network report","volume":"13","author":"Maurer\u2010Granofszky M.","year":"2021","journal-title":"Cancers"},{"issue":"21","key":"e_1_2_6_65_1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14215445","article-title":"Reliable flow\u2010cytometric approach for minimal residual disease monitoring in patients with B\u2010cell precursor acute lymphoblastic leukemia after CD19\u2010targeted therapy","volume":"14","author":"Mikhailova E.","year":"2022","journal-title":"Cancers"},{"issue":"5","key":"e_1_2_6_66_1","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/cyto.b.22088","article-title":"B\u2010lineage antigens that are useful to substitute CD19 for minimal residual disease monitoring in B cell precursor acute lymphoblastic leukemia after CD19 targeting","volume":"102","author":"Mikhailova E.","year":"2022","journal-title":"Cytometry. Part B, Clinical Cytometry"},{"issue":"2","key":"e_1_2_6_67_1","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/cyto.b.21515","article-title":"Quantitative flow cytometry: Concerns and recommendations in clinic and research","volume":"94","author":"Mizrahi O.","year":"2018","journal-title":"Cytometry Part B, Clinical Cytometry"},{"issue":"3","key":"e_1_2_6_68_1","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/cyto.b.22202","article-title":"Flow cytometry assay modifications: Recommendations for method validation based on CLSI H62 guidelines","volume":"108","author":"Monaghan S. A.","year":"2025","journal-title":"Cytometry Part B, Clinical Cytometry"},{"issue":"2","key":"e_1_2_6_69_1","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/ijlh.12755","article-title":"Relevance of sample preparation for flow cytometry","volume":"40","author":"Muccio V. E.","year":"2018","journal-title":"International Journal of Laboratory Hematology"},{"issue":"1","key":"e_1_2_6_70_1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41408-025-01279-9","article-title":"Novel humanized CD19\u2010CAR\u2010T (now talicabtagene autoleucel, Tali\u2010cel\u2122) cells in relapsed\/ refractory pediatric B\u2010acute lymphoblastic leukemia\u2010 an open\u2010label single\u2010arm phase\u2010I\/Ib study","volume":"15","author":"Narula G.","year":"2025","journal-title":"Blood Cancer Journal"},{"issue":"3","key":"e_1_2_6_71_1","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/cyto.a.22251","article-title":"Quantifying spillover spreading for comparing instrument performance and aiding in multicolor panel design","volume":"83","author":"Nguyen R.","year":"2013","journal-title":"Cytometry Part A: The Journal of the International Society for Analytical Cytology"},{"key":"e_1_2_6_72_1","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2020.00457","article-title":"Delphi technique in health sciences: A map","volume":"8","author":"Niederberger M.","year":"2020","journal-title":"Frontiers in Public Health"},{"key":"e_1_2_6_73_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2017.11.007","article-title":"How to make usage of the standardized EuroFlow 8\u2010color protocols possible for instruments of different manufacturers","volume":"475","author":"Nov\u00e1kov\u00e1 M.","year":"2019","journal-title":"Journal of Immunological Methods"},{"issue":"3","key":"e_1_2_6_74_1","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.cll.2007.05.009","article-title":"Quality control in clinical flow cytometry","volume":"27","author":"Oldaker T. A.","year":"2007","journal-title":"Clinics in Laboratory Medicine"},{"issue":"1","key":"e_1_2_6_75_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-023-00951-2","article-title":"Determining hemodilution in diagnostic bone marrow aspirated samples in plasma cell disorders by next\u2010generation flow cytometry: Proposal for a bone marrow quality index","volume":"13","author":"\u00d3skarsson J.","year":"2023","journal-title":"Blood Cancer Journal"},{"issue":"1","key":"e_1_2_6_76_1","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13045-019-0790-x","article-title":"Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: A retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT","volume":"12","author":"Pavl\u016f J.","year":"2019","journal-title":"Journal of Hematology & Oncology"},{"issue":"2","key":"e_1_2_6_77_1","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/cyto.b.22161","article-title":"Maturational dyssynchrony in benign B\u2010cell precursors following lymphocyte depleting chemotherapy: A potential pitfall for B\u2010lymphoblastic leukemia minimal\/measurable residual disease (MRD) flow cytometry analysis","volume":"106","author":"Placek A.","year":"2024","journal-title":"Cytometry Part B, Clinical Cytometry"},{"issue":"19","key":"e_1_2_6_78_1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13194924","article-title":"Reference values to assess hemodilution and warn of potential false\u2010negative minimal residual disease results in myeloma","volume":"13","author":"Puig N.","year":"2021","journal-title":"Cancers"},{"issue":"6","key":"e_1_2_6_79_1","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3109\/10428194.2011.559668","article-title":"Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody\u2010based immunotherapy in acute lymphoblastic leukemia: Analysis of 552 cases","volume":"52","author":"Raponi S.","year":"2011","journal-title":"Leukemia & Lymphoma"},{"issue":"11","key":"e_1_2_6_80_1","doi-asserted-by":"crossref","first-page":"E352","DOI":"10.1002\/ajh.25235","article-title":"Heterogeneity of surface CD19 and CD22 expression in B lymphoblastic leukemia","volume":"93","author":"Rosenthal J.","year":"2018","journal-title":"American Journal of Hematology"},{"issue":"3","key":"e_1_2_6_81_1","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1182\/blood.2022018905","article-title":"CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS","volume":"143","author":"Sakemura R. L.","year":"2024","journal-title":"Blood"},{"issue":"11","key":"e_1_2_6_82_1","doi-asserted-by":"crossref","first-page":"e586","DOI":"10.1016\/S1470-2045(25)00426-7","article-title":"Measurable residual disease\u2010guided interventions in patients with acute myeloid leukaemia undergoing allogeneic haematopoietic cell transplantation: Best practice recommendations from the European Society for Blood and Marrow Transplantation Practice Harmonisation and guidelines committee","volume":"26","author":"Sanz J.","year":"2025","journal-title":"The Lancet Oncology"},{"issue":"12","key":"e_1_2_6_83_1","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1080\/17474086.2018.1549479","article-title":"Measurable residual disease in acute myeloid leukemia using flow cytometry: Approaches for harmonization\/standardization","volume":"11","author":"Schuurhuis G. J.","year":"2018","journal-title":"Expert Review of Hematology"},{"issue":"14","key":"e_1_2_6_84_1","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1182\/bloodadvances.2022009379","article-title":"Assessment of acute myeloid leukemia molecular measurable residual disease testing in an interlaboratory study","volume":"7","author":"Scott S.","year":"2023","journal-title":"Blood Advances"},{"issue":"3","key":"e_1_2_6_85_1","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/cyto.b.21754","article-title":"Assessment of plasma cell myeloma minimal residual disease testing by flow cytometry in an international inter\u2010laboratory study: Is it ready for primetime use?","volume":"96","author":"Scott S. D.","year":"2019","journal-title":"Cytometry Part B, Clinical Cytometry"},{"issue":"1","key":"e_1_2_6_86_1","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1182\/blood-2024-208387","article-title":"A novel 12\u2010color 2\u2010tube next generation flow approach enables sensitive detection of measurable residual disease in virtually all T\u2010cell acute lymphoblastic leukemia patients","volume":"144","author":"Sedek L.","year":"2024","journal-title":"Blood"},{"key":"e_1_2_6_87_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2018.03.005","article-title":"Differential expression of CD73, CD86 and CD304 in normal vs. leukemic B\u2010cell precursors and their utility as stable minimal residual disease markers in childhood B\u2010cell precursor acute lymphoblastic leukemia","volume":"475","author":"S\u0119dek \u0141.","year":"2019","journal-title":"Journal of Immunological Methods"},{"issue":"1","key":"e_1_2_6_88_1","doi-asserted-by":"crossref","DOI":"10.1002\/cpcy.53","article-title":"Flow cytometry method validation protocols","volume":"87","author":"Selliah N.","year":"2019","journal-title":"Current Protocols in Cytometry"},{"issue":"5","key":"e_1_2_6_89_1","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1080\/10428194.2019.1709834","article-title":"A systematic review of outcomes after stem cell transplantation in acute lymphoblastic leukemia with or without measurable residual disease","volume":"61","author":"Shah S.","year":"2020","journal-title":"Leukemia & Lymphoma"},{"key":"e_1_2_6_90_1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1641088","article-title":"Expression of aberrant markers in monitoring of measurable residual disease in B\u2010cell precursor acute lymphoblastic leukemia patients during remission\u2010inducing therapy phase","volume":"15","author":"S\u0142ota \u0141.","year":"2025","journal-title":"Frontiers in Oncology"},{"issue":"2","key":"e_1_2_6_91_1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/cyto.b.21862","article-title":"Methodological considerations for the high sensitivity detection of multiple myeloma measurable residual disease","volume":"98","author":"Soh K. T.","year":"2020","journal-title":"Cytometry Part B, Clinical Cytometry"},{"issue":"1","key":"e_1_2_6_92_1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/cyto.a.21162","article-title":"CD304 is preferentially expressed on a subset of B\u2010lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry","volume":"81","author":"Solly F.","year":"2012","journal-title":"Cytometry Part A: The Journal of the International Society for Analytical Cytology"},{"issue":"9","key":"e_1_2_6_93_1","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/cyto.a.23844","article-title":"Standardization of flow cytometric immunophenotyping for hematological malignancies: The FranceFlow group experience","volume":"95","author":"Solly F.","year":"2019","journal-title":"Cytometry Part A: The Journal of the International Society for Analytical Cytology"},{"issue":"1","key":"e_1_2_6_94_1","doi-asserted-by":"crossref","first-page":"5882","DOI":"10.1182\/blood-2025-5882","article-title":"Pre\u2010treatment CD19 antigen density and multi\u2010antigen profiling by calibrated quantitative flow cytometry correlates with CAR T efficacy in LBCL","volume":"146","author":"Spiegel J.","year":"2025","journal-title":"Blood"},{"issue":"1","key":"e_1_2_6_95_1","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/cyto.b.21249","article-title":"Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition","volume":"90","author":"Stetler\u2010Stevenson M.","year":"2016","journal-title":"Cytometry Part B, Clinical Cytometry"},{"issue":"11","key":"e_1_2_6_96_1","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/cyto.a.22736","article-title":"Compensation in multicolor flow cytometry","volume":"87","author":"Szal\u00f3ki G.","year":"2015","journal-title":"Cytometry, Part A"},{"issue":"11","key":"e_1_2_6_97_1","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/cyto.a.22217","article-title":"In the realm for standardization in immunophenotyping","volume":"81","author":"T\u00e1rnok A.","year":"2012","journal-title":"Cytometry Part A: The Journal of the International Society for Analytical Cytology"},{"issue":"1","key":"e_1_2_6_98_1","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1182\/blood-2025-1596","article-title":"Hemodilution assessment for high\u2010sensitivity flow cytometric measurable residual disease evaluation in pediatric B\u2010cell acute lymphoblastic leukemia","volume":"146","author":"Tembhare P.","year":"2025","journal-title":"Blood"},{"issue":"6","key":"e_1_2_6_99_1","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1055\/s-0043-1772203","article-title":"Monitoring measurable\/minimal residual disease in acute myeloid leukemia: Multiparametric flow cytometry\u2010based approach","volume":"44","author":"Tembhare P. R.","year":"2023","journal-title":"Indian Journal of Medical and Paediatric Oncology"},{"issue":"4","key":"e_1_2_6_100_1","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/cyto.b.21939","article-title":"Eleven\u2010marker 10\u2010color flow cytometric assessment of measurable residual disease for T\u2010cell acute lymphoblastic leukemia using an approach of exclusion","volume":"100","author":"Tembhare P. R.","year":"2021","journal-title":"Cytometry Part B, Clinical Cytometry"},{"issue":"1","key":"e_1_2_6_101_1","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/cyto.b.21486","article-title":"Evaluation of new markers for minimal residual disease monitoring in B\u2010cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000\u2010000","volume":"94","author":"Tembhare P. R.","year":"2018","journal-title":"Cytometry Part B, Clinical Cytometry"},{"key":"e_1_2_6_102_1","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3389\/fonc.2020.00577","article-title":"Post\u2010induction measurable residual disease using multicolor flow cytometry is strongly predictive of inferior clinical outcome in the real\u2010life Management of Childhood T\u2010cell acute lymphoblastic leukemia: A study of 256 patients","volume":"10","author":"Tembhare P. R.","year":"2020","journal-title":"Frontiers in Oncology"},{"issue":"4","key":"e_1_2_6_103_1","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.63","article-title":"Circulating tumor plasma cells and peripheral blood measurable residual disease assessment in multiple myeloma patients not planned for upfront transplant","volume":"8","author":"Tembhare P. R.","year":"2024","journal-title":"HemaSphere"},{"issue":"1","key":"e_1_2_6_104_1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/cyto.b.21831","article-title":"A high\u2010sensitivity 10\u2010color flow cytometric minimal residual disease assay in B\u2010lymphoblastic leukemia\/lymphoma Can easily achieve the sensitivity of 2\u2010in\u201010(6) and is superior to standard minimal residual disease assay: A study of 622 patients","volume":"98","author":"Tembhare P. R.","year":"2020","journal-title":"Cytometry Part B, Clinical Cytometry"},{"issue":"1","key":"e_1_2_6_105_1","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000676","article-title":"Technical aspects of flow cytometry\u2010based measurable residual disease quantification in acute myeloid leukemia: Experience of the European LeukemiaNet MRD working party","volume":"6","author":"Tettero J. M.","year":"2022","journal-title":"HemaSphere"},{"issue":"3","key":"e_1_2_6_106_1","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41375-024-02158-1","article-title":"Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemia","volume":"38","author":"Tettero J. M.","year":"2024","journal-title":"Leukemia"},{"issue":"3","key":"e_1_2_6_107_1","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1182\/blood-2016-07-726307","article-title":"Standardized flow cytometry for highly sensitive MRD measurements in B\u2010cell acute lymphoblastic leukemia","volume":"129","author":"Theunissen P.","year":"2017","journal-title":"Blood"},{"issue":"3","key":"e_1_2_6_108_1","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/ijlh.12795","article-title":"Role of CD81 and CD58 in minimal residual disease detection in pediatric B lymphoblastic leukemia","volume":"40","author":"Tsitsikov E.","year":"2018","journal-title":"International Journal of Laboratory Hematology"},{"issue":"20","key":"e_1_2_6_109_1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15205064","article-title":"Measurable residual disease (MRD) by flow cytometry in adult B\u2010acute lymphoblastic Leukaemia (B\u2010ALL) and acute myeloid Leukaemia (AML): Correlation with molecular MRD testing and clinical outcome at one year","volume":"15","author":"Linde R.","year":"2023","journal-title":"Cancers"},{"issue":"5","key":"e_1_2_6_110_1","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jmoldx.2021.01.009","article-title":"Validation of a PCR\u2010based next\u2010generation sequencing approach for the detection and quantification of minimal residual disease in acute lymphoblastic leukemia and multiple myeloma using gBlocks as calibrators","volume":"23","author":"Van der Straeten J.","year":"2021","journal-title":"The Journal of Molecular Diagnostics"},{"issue":"26","key":"e_1_2_6_111_1","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1182\/blood-2015-03-580027","article-title":"Minimal residual disease diagnostics in acute lymphoblastic leukemia: Need for sensitive, fast, and standardized technologies","volume":"125","author":"Dongen J. J.","year":"2015","journal-title":"Blood"},{"issue":"1","key":"e_1_2_6_112_1","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjh.17992","article-title":"Flow cytometric minimal residual disease assessment in B\u2010cell precursor acute lymphoblastic leukaemia patients treated with CD19\u2010targeted therapies \u2010 a EuroFlow study","volume":"197","author":"Verbeek M. W. C.","year":"2022","journal-title":"British Journal of Haematology"},{"issue":"4","key":"e_1_2_6_113_1","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70125","article-title":"Minimal residual disease assessment following CD19\u2010targeted therapy in B\u2010cell precursor acute lymphoblastic leukemia using standardized 12\u2010color flow cytometry: A EuroFlow study","volume":"9","author":"Verbeek M. W. C.","year":"2025","journal-title":"HemaSphere"},{"issue":"1","key":"e_1_2_6_114_1","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/ijlh.13974","article-title":"Effects of CD34(+) cell dose on haematopoietic recovery in acute lymphoblastic leukaemia patients with positive pretransplant measurable residual disease","volume":"45","author":"Wang Y.","year":"2023","journal-title":"International Journal of Laboratory Hematology"},{"key":"e_1_2_6_115_1","doi-asserted-by":"crossref","DOI":"10.1177\/1177390118757462","article-title":"Ten basic rules of antibody validation","volume":"13","author":"Weller M. G.","year":"2018","journal-title":"Analytical Chemistry Insights"},{"key":"e_1_2_6_116_1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/978-1-62703-357-2_8","article-title":"Flow cytometric monitoring of residual disease in acute leukemia","volume":"999","author":"Wood B. L.","year":"2013","journal-title":"Methods in Molecular Biology (Clifton, N.J.)"},{"issue":"1","key":"e_1_2_6_117_1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/cyto.b.21239","article-title":"Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry","volume":"90","author":"Wood B. L.","year":"2016","journal-title":"Cytometry Part B, Clinical Cytometry"},{"issue":"1","key":"e_1_2_6_118_1","first-page":"S14","article-title":"Bethesda international consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: Optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia","volume":"72","author":"Wood B. L.","year":"2006","journal-title":"Cytometry Part B, Clinical Cytometry"},{"issue":"8","key":"e_1_2_6_119_1","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27787","article-title":"Clinical benefit of a high\u2010throughput sequencing approach for minimal residual disease in acute lymphoblastic leukemia","volume":"66","author":"Wright G.","year":"2019","journal-title":"Pediatric Blood & Cancer"},{"key":"e_1_2_6_120_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.934442","article-title":"Comparable outcomes in patients with B\u2010cell acute lymphoblastic leukemia receiving haploidentical hematopoietic stem cell transplantation: Pretransplant minimal residual disease\u2010negative complete remission following chimeric antigen receptor T\u2010cell therapy versus chemotherapy","volume":"13","author":"Yang T. T.","year":"2022","journal-title":"Frontiers in Immunology"}],"container-title":["Cytometry Part B: Clinical Cytometry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cyto.b.70055","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cyto.b.70055","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cyto.b.70055","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:03:18Z","timestamp":1785841398000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cyto.b.70055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":119,"alternative-id":["10.1002\/cyto.b.70055"],"URL":"https:\/\/doi.org\/10.1002\/cyto.b.70055","archive":["Portico"],"relation":{},"ISSN":["1552-4949","1552-4957"],"issn-type":[{"value":"1552-4949","type":"print"},{"value":"1552-4957","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"assertion":[{"value":"2026-04-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"cyto.b.70055"}}